Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
The purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with CD30-positive cancers and to determine the main route of excretion. The study will also assess blood drug levels in patients with renal or hepatic impairment (special populations).
Carcinomas|Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin|Neoplasms
DRUG: brentuximab vedotin|DRUG: rifampin|DRUG: midazolam|DRUG: ketoconazole|DRUG: brentuximab vedotin
Midazolam blood concentrations +/- brentuximab vedotin, 3 weeks|Brentuximab vedotin blood concentrations +/- rifampin, 6 weeks|Brentuximab vedotin in urine, feces, and blood, 1 week|Brentuximab vedotin blood concentrations in special populations, 3 weeks|Brentuximab vedotin blood concentrations +/- ketoconazole, 6 weeks
Incidence of adverse events and laboratory abnormalities, 6 weeks
The purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with CD30-positive cancers and to determine the main route of excretion. The study will also assess blood drug levels in patients with renal or hepatic impairment (special populations).